GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SillaJen 215600.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

1,959

-0.05%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SillaJen

Its shares trade on KOSDAQ under the ticker 215600.KQ. It has been listed since 6 December 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩9.23bn and a net loss of ₩24.19bn. At that date it held total assets of ₩116.81bn and shareholders' equity of ₩110.12bn.

SillaJen, Inc. develops oncolytic immunotherapeutics virus. The company is headquartered in Seoul, Seoul. The company went IPO on 2016-12-06. The Company’s major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
6 Dec 2016

Leadership

Pay as last reported

  • Mr. Tae Gyun KimPresident
  • Mr. Jae Gyeong KimChief Executive Officer, Director, since 2021
  • Mr. Sang Geun ParkManaging Director, since 2021
  • Sang Gyu HanManaging Director
  • Mr. Mun Gi ChoiAssistant Managing Director
  • Mr. Eun Su KimInternal Auditor
  • Ms. Geun Hui OhAssistant Managing Director
  • Ms. Susanna ShinAssistant Managing Director
  • Mr. Yong Jae JangNon-Executive Independent Director
  • Mr. Byeong Wuk JungNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
26
Environment
30
Social
14
Governance
33
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pexa-Vec is in global Phase 3 trials for liver cancer treatment.
  • SillaJen offers multiple oncolytic virus immunotherapeutics including SJ-102 and SJ-103.
  • The company's headquarters in Seoul supports biotechnology innovation in South Korea.

Weaknesses

  • Pexa-Vec is still in Phase 3 clinical trials without approval.
  • The company has limited product approval beyond clinical trials.
  • SillaJen's focus on oncolytic viruses may face competition in biotechnology.

Opportunities

  • Global Phase 3 trials for Pexa-Vec could lead to market approval.
  • Expansion into liver cancer treatment markets in Asia and Europe.
  • Growing demand for oncolytic virus therapies in the biotechnology sector.

Threats

  • Failure of Pexa-Vec in Phase 3 trials could delay market entry.
  • Competition from other biotechnology firms in immunotherapy.
  • Regulatory hurdles in global markets for new cancer treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.